



Misdiagnosis of hemifacial spasm is a 
frequent event in the primary care setting
Erro diagnóstico do espasmo hemifacial é ocorrência frequente em unidades primárias de 
atenção à saúde 
Alberto R. M. Martinez1, Marcelo B. Nunes1, Nayara D. Immich2, Luiza Piovesana1, Marcondes França Jr.1, 
Lidiane S. Campos1, Anelyssa D’Abreu1
Hemifacial spasm (HFS) is a peripherally-induced move-
ment disorder characterized by progressive, involuntary and 
a painless form of a segmental myoclonus expressed by tonic 
or clonic unilateral facial muscle contractions in the territo-
ry innervated by ipsilateral seventh cranial nerve1-3. Generally 
the muscle twitch involves initially the periocular region but 
as it progresses, virtually all facial muscles could be affected3-5.
First described by Schültze in 1875, in a 56-year-old man 
with a 10-year history of involuntary movements involving 
the left side of the face6, HFS has been reported in large series 
of cases worldwide, the age-adjusted annual incidence was 
0.78/100.000 in a study in Rochester and Olmsted County – 
Minnesota7 and the overall prevalence is about 10/100.0001,8,9.
Compression of the facial nerve at the root exit zone gen-
erally by vascular abnormalities is the most accepted hypoth-
esis for HFS etiology3,4. Chung and cols described 1642 pa-
tients with HFS in which vascular compression of the facial 
nerve was responsible for 99.4% of the cases. The remaining 
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AbstrACt
Primary hemifacial spasm (HFS) is characterized by irregular and involuntary contraction of the muscles innervated by the ipsilateral fa-
cial nerve. Treatment controls symptoms and improves quality of life (QoL). Objective: Evaluate the initial diagnosis and treatment of HFS 
prior to referral to a tertiary center. Method: We interviewed through a standard questionnaire 66 patients currently followed in our center. 
results: Mean age: 64.19±11.6 years, mean age of symptoms onset: 51.9±12.5 years, male/female ratio of 1:3. None of the patients had 
a correct diagnosis in their primary care evaluation. Medication was prescribed to 56.8%. Mean time from symptom onset to botulinum 
toxin treatment: 4.34 ±7.1 years, with a 95% satisfaction. Thirty percent presented social embarrassment due to HFS. Conclusion: Despite 
its relatively straightforward diagnosis, all patients had an incorrect diagnosis and treatment on their first evaluation. HFS brings social 
impairment and the delay in adequate treatment negatively impacts QoL.
Keywords: hemifacial spasm, misdiagnosis, botulinum toxin.
rEsuMO
Espasmo hemifacial primário é caracterizado pela contração irregular ou involuntária dos músculos inervados pelo nervo facial ipsilateral. 
O tratamento é eficaz para controlar sintomas e melhorar a qualidade de vida. Objetivo: Avaliar diagnóstico e tratamento do espasmo he-
mifacial primário feitos antes do encaminhamento ao centro terciário. Método: Foram coletados retrospectivamente dados de 66 pacien-
tes atualmente acompanhados no nosso serviço através de entrevista padronizada. resultados: Média de idade: 64,19±11,6 anos; média 
de idade no início dos sintomas: 51,9±12,5 anos; razão homem/mulher de 1:3. Nenhum dos pacientes foi corretamente diagnosticado na 
primeira avaliação. Foram prescritos medicamentos para 56,8%. O tempo médio entre início dos sintomas e o tratamento com toxina bo-
tulínica foi 4,34±7,1 anos; 95% ficaram satisfeitos com o tratamento; 30% tinham constrangimento social. Conclusão: Embora seja uma 
condição de relativa facilidade diagnóstica, todos os pacientes tiveram diagnóstico e tratamento incorretos na primeira avaliação. Espas-
mo hemifacial primário traz constrangimento social, agravado pelo atraso no tratamento adequado.
Palavras-chave: espasmo hemifacial, diagnóstico, toxina botulínica.
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cases (0.6%) were composed by masses or arterivenous mal-
formation10. Although the vascular etiology is accepted, the 
evidence of a neurovascular conflict is present in 25% of as-
ymptomatic subjects, leading to the fact that the HFS could 
not be explained only by the neurovascular compression1,8.
Although not life threatening, the paroxystic and chronic 
facial contractions in HFS significantly interferes in the ac-
tivities of daily living and social activities with a major im-
pact in quality of life (QoL)5,11,12. Psychiatric disorders such as 
obsessive symptoms are also associated to HFS13. Treatment 
options vary from surgical with a microvascular decompres-
sion procedure to botulinum toxin (BoNT) injections, the last 
accepted as the first treatment option considering the poten-
tial risks of a neurosurgical treatment1.
Hence, the delay in the diagnosis is unacceptable. HFS 
is highly detrimental to social functioning and QoL and the 
condition is easily investigated and treated. In this study, we 
aim to access the misdiagnoses of the HFS patients prior to 
referral to a tertiary movement disorder clinic.
METHOD
A retrospective study was performed through the review 
of the medical records which included the referral forms from 
the primary care centers and therefore the diagnosis made, if 
there was any. These data were complemented by a systemat-
ic interview of 66 patients diagnosed with HFS and followed 
in a Tertiary Movement Disorders Outpatient Clinic at the 
University Hospital of UNICAMP, São Paulo, Brazil. Data col-
lected from the 66 patients included: general demographics; 
time from onset of symptoms and diagnosis of HFS; diagno-
sis given prior to HFS; treatment established prior to BoNT 
and its efficacy; time from diagnosis and BoNT treatment; 
years of BoNT treatment and satisfaction with it; review of 
employment history and social impairment due to HFS and 
the perception of the patients themselves about their condi-
tion considering what they were told in previous consulta-
tions. For statistical analysis we used Systat 9. Demographic 
and clinical data are presented in measures of central ten-
dency (mean) and dispersion (standard deviation). This 
study was approved by the Ethical Committee of UNICAMP 
no. 924/2010.
RESULTS
We included 50 female patients (75.7%) and 16 male 
patients (24.3%). The mean age at time of interview was 
64.19±11.6 years ranging from 31 to 84 years. Mean age of 
symptoms onset was 51.9±12.5 years (range 13-75) and 
mean time from first symptom to proper HFS diagnosis was 
2.64±3.8 years (0-20 years). Total time in years since HFS 
onset to the last evaluation was 12.4±10.1 (1.08-64 years). 
Demographic data is summarized in Table.
None of the patients had HFS as their first diagnosis. All 
patients were seen by their family physicians or a general 
practitioner. Surprisingly, 29 of out 66 (43.9%) not even re-
ceived a differential diagnosis at the primary care services 
and, for those who did, the most frequent hypothesis were: 
functional disorder (or psychogenic) in 25/66 (37.8%), facial 
palsy in 6/66 (9%), tics in 2/66 (3%) and a miscellaneous 
group (Figure). In some cases, more than one “hypothesis” 
was made. When the patients were asked about their percep-
tion regarding their condition from the consultations prior 
to the referral, most of them (61 patients) were not able to 
describe their diagnosis and some reported anecdotal diag-
nosis, such as dental issues (2 cases), “aging issues” (1 case), 
vitamin deficiency (1 case) or “brain failure” (1 case).
Before referral, the initial treatment option was a pre-
scription medicine in 35/66 (53%) of cases, which included 
benzodiazepines in 25.36%, anxiolytics in 17.9%, carbamaze-
pine in 8.9%, vitamins and antihypertensive drugs. Among 
these patients receiving oral medication, 6/35 (17%) referred 
partial or transient improvement of facial contractions, but 
none had a sustained response. Two patients were referred 
for surgical evaluation and two underwent dental extraction 
for symptomatic improvement.
Prior to botulinum toxin A (BoNT) injections, 31/66 pa-
tients opted to start oral medication, but only 17% presented 
a partial response. BoNT injections were scheduled as soon 
as they were referred to the Tertiary Movement Disorders 
Clinic. Mean time from symptom onset to BoNT treatment 
was 5.34±7.1 years (range 0-20). Ninety-five percent of the 
table. Demographic data of 66 patients with HSF.
Age (y) 64.19±11.6 (31-84)
Sex (M:F) 1:3
Age at HFS onset (y) 51.9±12.5 (13-75)
Duration of HFS (y) 12.4±10.1 (1.08-64)
Mean time from symptoms to BoNT injections (y) 5.34±7.1 (0-20)
Follow-up with BoNT (y) 7.1 ± 6
BoNT personal satisfaction (%) 95
Figure. Different first diagnosis of hemifacial spasm patients. 
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patients were satisfied with their current treatment after a 
mean follow-up of 7.1±6 years.
By the time patients arrived at our center, 50% of them 
were unemployed, and during the followup, 30% still com-
plained of limiting social activities because of the HFS.
DISCUSSION
Even though HFS is not a common disease, with an es-
timated prevalence of 10/1000001,7,9, the diagnosis of HFS is 
imminently based on clinical grounds. As far as we know, 
this is the first study to evaluate the accuracy of the diagno-
sis at the first assessment and the time elapsed between the 
first evaluation and the use of the correct treatment. The 
general demographic data of the sample presented is con-
sistent with previous HFS series1,3,4,10,13, although the mean 
age of symptoms onset was slightly higher than in another 
study in a Brazilian population18.
Tan and cols19 made a video evaluation among 209 family 
physicians showing 2 patients with HFS and inquiring about 
the correct diagnosis and treatment. Only 9.4% (19/203) 
made the correct diagnosis, while the others either gave the 
wrong diagnosis or opted for the “don’t know” answer.
Some semiological tools are helpful in order to make the 
correct diagnosis. Stamey and Jankovic tested “the other 
Babinski sign” or “the brow-lift sign” (“when orbicularis oculi 
contracts and the eye closes, the internal part of the frontalis 
contracts at the same time, the eyebrow rises during eye oc-
clusion,” and “this set of occurrences is impossible to repro-
duce by will” ). The authors found that the sign’s sensitivity to 
diagnose HFS was 25.3%, specificity was 100%, and positive 
predictive value was 100%14.
Although easily recognized by a trained neurologist, the 
list of possible differential diagnosis for HFS includes tics, 
myokymia, blepharospasm, tardive dyskinesia, focal sei-
zure, masticatory spasm, cranial dystonia and others1,3,8. 
In our sample, a significant proportion of our patients not 
even received a single diagnostic hypothesis in 43.9% of pa-
tients, referring them to the tertiary center for investigation 
of facial movements. Most patients who received one, had a 
diagnosis of a functional movement disorder (psychogenic) 
which led to a significant delay in proper treatment. Even 
though psychiatric symptoms, such as obsessive and com-
pulsive symptoms, have been described in a Brazillian se-
ries of HFS patients13, a psychogenic etiology was not found 
in any of our patients.
The treatment options for HFS patients include: simple 
massage, oral medication, microvascular decompression and 
regular BoNT injections, which is considered the first line 
treatment1,3,5. Medication used to HFS includes carbamaze-
pine, clonazepam, phenytoin, gababentin and baclofen with a 
mild clinical response verified in other series varying from 8 to 
16.6%1,3,8. Our series showed similar data with a mild/transient 
medication response in 17% of those who received oral medi-
cation. A proportion of patients received oral treatment with a 
large array of medications even though they did not receive a 
diagnosis. BoNT injections reached good/excellent results in 
76-100% of patients according to previous series1,10,18.
Misdiagnosis leads to a direct impact in QoL, social dis-
tress and impairment in activities of daily living such as driv-
ing or reading3,5,10,11. Nearly 50% of the patients evaluated in 
this series were unemployed by the time they reached the 
tertiary center and considered HFS as a contributing factor 
for this status. A third was still facing social limitations at-
tributed to HFS.
Although HFS is not a life-threatening condition, it brings 
significant social and physical impairment that is greatly pro-
longed by an incorrect diagnosis. Prescription medication 
can bring a mild symptomatic relief, but BoNT injections lead 
to a much higher rate of personal satisfaction. Continuous 
education in the most prevalent movement disorders should 
be encouraged on primary care grounds in order to diminish 
unnecessary delay in treatment and diagnosis.
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